nodes	percent_of_prediction	percent_of_DWPC	metapath
Zuclopenthixol—HTR2A—urine—urinary bladder cancer	0.0049	0.111	CbGeAlD
Zuclopenthixol—CYP2D6—urine—urinary bladder cancer	0.00446	0.101	CbGeAlD
Zuclopenthixol—DRD5—female reproductive system—urinary bladder cancer	0.00322	0.0731	CbGeAlD
Zuclopenthixol—ADRA1A—prostate gland—urinary bladder cancer	0.00272	0.0617	CbGeAlD
Zuclopenthixol—HRH1—prostate gland—urinary bladder cancer	0.00211	0.0477	CbGeAlD
Zuclopenthixol—ADRA2A—prostate gland—urinary bladder cancer	0.00207	0.0469	CbGeAlD
Zuclopenthixol—ADRA1A—epithelium—urinary bladder cancer	0.002	0.0453	CbGeAlD
Zuclopenthixol—ADRA1A—renal system—urinary bladder cancer	0.00185	0.042	CbGeAlD
Zuclopenthixol—ADRA2A—seminal vesicle—urinary bladder cancer	0.00175	0.0396	CbGeAlD
Zuclopenthixol—HRH1—epithelium—urinary bladder cancer	0.00155	0.0351	CbGeAlD
Zuclopenthixol—HRH1—smooth muscle tissue—urinary bladder cancer	0.00149	0.0338	CbGeAlD
Zuclopenthixol—HRH1—urethra—urinary bladder cancer	0.00141	0.032	CbGeAlD
Zuclopenthixol—ADRA2A—urethra—urinary bladder cancer	0.00138	0.0314	CbGeAlD
Zuclopenthixol—HTR2A—epithelium—urinary bladder cancer	0.00129	0.0293	CbGeAlD
Zuclopenthixol—HTR2A—smooth muscle tissue—urinary bladder cancer	0.00124	0.0282	CbGeAlD
Zuclopenthixol—HTR2A—renal system—urinary bladder cancer	0.0012	0.0272	CbGeAlD
Zuclopenthixol—HRH1—female reproductive system—urinary bladder cancer	0.00115	0.026	CbGeAlD
Zuclopenthixol—ADRA2A—female reproductive system—urinary bladder cancer	0.00113	0.0256	CbGeAlD
Zuclopenthixol—CYP2D6—renal system—urinary bladder cancer	0.00109	0.0247	CbGeAlD
Zuclopenthixol—HRH1—vagina—urinary bladder cancer	0.00104	0.0236	CbGeAlD
Zuclopenthixol—ADRA2A—vagina—urinary bladder cancer	0.00102	0.0231	CbGeAlD
Zuclopenthixol—HTR2A—female reproductive system—urinary bladder cancer	0.00096	0.0218	CbGeAlD
Zuclopenthixol—Rash—Thiotepa—urinary bladder cancer	0.000956	0.001	CcSEcCtD
Zuclopenthixol—Dermatitis—Thiotepa—urinary bladder cancer	0.000955	0.000999	CcSEcCtD
Zuclopenthixol—Agranulocytosis—Methotrexate—urinary bladder cancer	0.000955	0.000999	CcSEcCtD
Zuclopenthixol—Headache—Thiotepa—urinary bladder cancer	0.00095	0.000994	CcSEcCtD
Zuclopenthixol—Decreased appetite—Etoposide—urinary bladder cancer	0.000947	0.000991	CcSEcCtD
Zuclopenthixol—Pancytopenia—Doxorubicin—urinary bladder cancer	0.000944	0.000987	CcSEcCtD
Zuclopenthixol—Gastrointestinal disorder—Etoposide—urinary bladder cancer	0.00094	0.000984	CcSEcCtD
Zuclopenthixol—Body temperature increased—Cisplatin—urinary bladder cancer	0.00094	0.000983	CcSEcCtD
Zuclopenthixol—Fatigue—Etoposide—urinary bladder cancer	0.000939	0.000982	CcSEcCtD
Zuclopenthixol—Jaundice—Epirubicin—urinary bladder cancer	0.000933	0.000976	CcSEcCtD
Zuclopenthixol—Pain—Etoposide—urinary bladder cancer	0.000931	0.000974	CcSEcCtD
Zuclopenthixol—Constipation—Etoposide—urinary bladder cancer	0.000931	0.000974	CcSEcCtD
Zuclopenthixol—Neutropenia—Doxorubicin—urinary bladder cancer	0.000929	0.000972	CcSEcCtD
Zuclopenthixol—Dysuria—Doxorubicin—urinary bladder cancer	0.000929	0.000972	CcSEcCtD
Zuclopenthixol—Hypersensitivity—Fluorouracil—urinary bladder cancer	0.000924	0.000967	CcSEcCtD
Zuclopenthixol—Sweating—Epirubicin—urinary bladder cancer	0.000918	0.00096	CcSEcCtD
Zuclopenthixol—Asthenia—Gemcitabine—urinary bladder cancer	0.000915	0.000957	CcSEcCtD
Zuclopenthixol—Urinary tract disorder—Methotrexate—urinary bladder cancer	0.000907	0.000949	CcSEcCtD
Zuclopenthixol—Photosensitivity reaction—Doxorubicin—urinary bladder cancer	0.000907	0.000949	CcSEcCtD
Zuclopenthixol—Hepatobiliary disease—Epirubicin—urinary bladder cancer	0.000905	0.000947	CcSEcCtD
Zuclopenthixol—Weight increased—Doxorubicin—urinary bladder cancer	0.000904	0.000946	CcSEcCtD
Zuclopenthixol—Pruritus—Gemcitabine—urinary bladder cancer	0.000903	0.000944	CcSEcCtD
Zuclopenthixol—Nausea—Thiotepa—urinary bladder cancer	0.000901	0.000942	CcSEcCtD
Zuclopenthixol—Urethral disorder—Methotrexate—urinary bladder cancer	0.0009	0.000942	CcSEcCtD
Zuclopenthixol—Weight decreased—Doxorubicin—urinary bladder cancer	0.000899	0.00094	CcSEcCtD
Zuclopenthixol—Feeling abnormal—Etoposide—urinary bladder cancer	0.000898	0.000939	CcSEcCtD
Zuclopenthixol—Hyperglycaemia—Doxorubicin—urinary bladder cancer	0.000896	0.000938	CcSEcCtD
Zuclopenthixol—Agranulocytosis—Epirubicin—urinary bladder cancer	0.000893	0.000935	CcSEcCtD
Zuclopenthixol—Gastrointestinal pain—Etoposide—urinary bladder cancer	0.000891	0.000932	CcSEcCtD
Zuclopenthixol—Pruritus—Fluorouracil—urinary bladder cancer	0.000887	0.000928	CcSEcCtD
Zuclopenthixol—Drowsiness—Doxorubicin—urinary bladder cancer	0.000886	0.000927	CcSEcCtD
Zuclopenthixol—Visual impairment—Methotrexate—urinary bladder cancer	0.000885	0.000926	CcSEcCtD
Zuclopenthixol—Hypersensitivity—Cisplatin—urinary bladder cancer	0.000876	0.000916	CcSEcCtD
Zuclopenthixol—CYP2D6—female reproductive system—urinary bladder cancer	0.000874	0.0198	CbGeAlD
Zuclopenthixol—Diarrhoea—Gemcitabine—urinary bladder cancer	0.000873	0.000913	CcSEcCtD
Zuclopenthixol—HTR2A—vagina—urinary bladder cancer	0.000868	0.0197	CbGeAlD
Zuclopenthixol—Jaundice—Doxorubicin—urinary bladder cancer	0.000863	0.000903	CcSEcCtD
Zuclopenthixol—Body temperature increased—Etoposide—urinary bladder cancer	0.000861	0.000901	CcSEcCtD
Zuclopenthixol—Abdominal pain—Etoposide—urinary bladder cancer	0.000861	0.000901	CcSEcCtD
Zuclopenthixol—Eye disorder—Methotrexate—urinary bladder cancer	0.000858	0.000898	CcSEcCtD
Zuclopenthixol—Diarrhoea—Fluorouracil—urinary bladder cancer	0.000858	0.000898	CcSEcCtD
Zuclopenthixol—Tinnitus—Methotrexate—urinary bladder cancer	0.000856	0.000896	CcSEcCtD
Zuclopenthixol—Asthenia—Cisplatin—urinary bladder cancer	0.000853	0.000892	CcSEcCtD
Zuclopenthixol—Cardiac disorder—Methotrexate—urinary bladder cancer	0.000852	0.000892	CcSEcCtD
Zuclopenthixol—Sweating—Doxorubicin—urinary bladder cancer	0.000849	0.000888	CcSEcCtD
Zuclopenthixol—Urinary tract disorder—Epirubicin—urinary bladder cancer	0.000849	0.000888	CcSEcCtD
Zuclopenthixol—Oedema peripheral—Epirubicin—urinary bladder cancer	0.000847	0.000886	CcSEcCtD
Zuclopenthixol—Connective tissue disorder—Epirubicin—urinary bladder cancer	0.000845	0.000884	CcSEcCtD
Zuclopenthixol—Urethral disorder—Epirubicin—urinary bladder cancer	0.000842	0.000881	CcSEcCtD
Zuclopenthixol—Hepatobiliary disease—Doxorubicin—urinary bladder cancer	0.000838	0.000876	CcSEcCtD
Zuclopenthixol—Angiopathy—Methotrexate—urinary bladder cancer	0.000833	0.000872	CcSEcCtD
Zuclopenthixol—Immune system disorder—Methotrexate—urinary bladder cancer	0.00083	0.000868	CcSEcCtD
Zuclopenthixol—Dizziness—Fluorouracil—urinary bladder cancer	0.000829	0.000868	CcSEcCtD
Zuclopenthixol—Visual impairment—Epirubicin—urinary bladder cancer	0.000828	0.000866	CcSEcCtD
Zuclopenthixol—Agranulocytosis—Doxorubicin—urinary bladder cancer	0.000827	0.000865	CcSEcCtD
Zuclopenthixol—Diarrhoea—Cisplatin—urinary bladder cancer	0.000814	0.000851	CcSEcCtD
Zuclopenthixol—Vomiting—Gemcitabine—urinary bladder cancer	0.000811	0.000849	CcSEcCtD
Zuclopenthixol—Mental disorder—Methotrexate—urinary bladder cancer	0.000805	0.000842	CcSEcCtD
Zuclopenthixol—Rash—Gemcitabine—urinary bladder cancer	0.000804	0.000841	CcSEcCtD
Zuclopenthixol—Dermatitis—Gemcitabine—urinary bladder cancer	0.000804	0.000841	CcSEcCtD
Zuclopenthixol—Eye disorder—Epirubicin—urinary bladder cancer	0.000803	0.00084	CcSEcCtD
Zuclopenthixol—Hypersensitivity—Etoposide—urinary bladder cancer	0.000803	0.00084	CcSEcCtD
Zuclopenthixol—Tinnitus—Epirubicin—urinary bladder cancer	0.000801	0.000838	CcSEcCtD
Zuclopenthixol—Malnutrition—Methotrexate—urinary bladder cancer	0.000799	0.000836	CcSEcCtD
Zuclopenthixol—Erythema—Methotrexate—urinary bladder cancer	0.000799	0.000836	CcSEcCtD
Zuclopenthixol—Headache—Gemcitabine—urinary bladder cancer	0.000799	0.000836	CcSEcCtD
Zuclopenthixol—Cardiac disorder—Epirubicin—urinary bladder cancer	0.000798	0.000834	CcSEcCtD
Zuclopenthixol—Vomiting—Fluorouracil—urinary bladder cancer	0.000797	0.000834	CcSEcCtD
Zuclopenthixol—Rash—Fluorouracil—urinary bladder cancer	0.000791	0.000827	CcSEcCtD
Zuclopenthixol—Dermatitis—Fluorouracil—urinary bladder cancer	0.00079	0.000827	CcSEcCtD
Zuclopenthixol—Headache—Fluorouracil—urinary bladder cancer	0.000786	0.000822	CcSEcCtD
Zuclopenthixol—Urinary tract disorder—Doxorubicin—urinary bladder cancer	0.000785	0.000822	CcSEcCtD
Zuclopenthixol—Oedema peripheral—Doxorubicin—urinary bladder cancer	0.000783	0.00082	CcSEcCtD
Zuclopenthixol—Asthenia—Etoposide—urinary bladder cancer	0.000782	0.000818	CcSEcCtD
Zuclopenthixol—Connective tissue disorder—Doxorubicin—urinary bladder cancer	0.000781	0.000818	CcSEcCtD
Zuclopenthixol—Angiopathy—Epirubicin—urinary bladder cancer	0.00078	0.000816	CcSEcCtD
Zuclopenthixol—Urethral disorder—Doxorubicin—urinary bladder cancer	0.00078	0.000815	CcSEcCtD
Zuclopenthixol—Immune system disorder—Epirubicin—urinary bladder cancer	0.000776	0.000812	CcSEcCtD
Zuclopenthixol—Pruritus—Etoposide—urinary bladder cancer	0.000771	0.000806	CcSEcCtD
Zuclopenthixol—Arrhythmia—Epirubicin—urinary bladder cancer	0.000768	0.000803	CcSEcCtD
Zuclopenthixol—Visual impairment—Doxorubicin—urinary bladder cancer	0.000766	0.000802	CcSEcCtD
Zuclopenthixol—Nausea—Gemcitabine—urinary bladder cancer	0.000758	0.000793	CcSEcCtD
Zuclopenthixol—Vomiting—Cisplatin—urinary bladder cancer	0.000756	0.000791	CcSEcCtD
Zuclopenthixol—Vision blurred—Methotrexate—urinary bladder cancer	0.000753	0.000788	CcSEcCtD
Zuclopenthixol—Mental disorder—Epirubicin—urinary bladder cancer	0.000753	0.000788	CcSEcCtD
Zuclopenthixol—Rash—Cisplatin—urinary bladder cancer	0.00075	0.000784	CcSEcCtD
Zuclopenthixol—Dermatitis—Cisplatin—urinary bladder cancer	0.000749	0.000784	CcSEcCtD
Zuclopenthixol—Malnutrition—Epirubicin—urinary bladder cancer	0.000748	0.000783	CcSEcCtD
Zuclopenthixol—Erythema—Epirubicin—urinary bladder cancer	0.000748	0.000783	CcSEcCtD
Zuclopenthixol—Diarrhoea—Etoposide—urinary bladder cancer	0.000745	0.00078	CcSEcCtD
Zuclopenthixol—Nausea—Fluorouracil—urinary bladder cancer	0.000745	0.000779	CcSEcCtD
Zuclopenthixol—Eye disorder—Doxorubicin—urinary bladder cancer	0.000743	0.000777	CcSEcCtD
Zuclopenthixol—Ill-defined disorder—Methotrexate—urinary bladder cancer	0.000742	0.000776	CcSEcCtD
Zuclopenthixol—Tinnitus—Doxorubicin—urinary bladder cancer	0.000741	0.000776	CcSEcCtD
Zuclopenthixol—Cardiac disorder—Doxorubicin—urinary bladder cancer	0.000738	0.000772	CcSEcCtD
Zuclopenthixol—Flatulence—Epirubicin—urinary bladder cancer	0.000737	0.000771	CcSEcCtD
Zuclopenthixol—Tension—Epirubicin—urinary bladder cancer	0.000734	0.000768	CcSEcCtD
Zuclopenthixol—Nervousness—Epirubicin—urinary bladder cancer	0.000727	0.00076	CcSEcCtD
Zuclopenthixol—Angiopathy—Doxorubicin—urinary bladder cancer	0.000721	0.000755	CcSEcCtD
Zuclopenthixol—Malaise—Methotrexate—urinary bladder cancer	0.000721	0.000754	CcSEcCtD
Zuclopenthixol—Dizziness—Etoposide—urinary bladder cancer	0.00072	0.000754	CcSEcCtD
Zuclopenthixol—Immune system disorder—Doxorubicin—urinary bladder cancer	0.000718	0.000751	CcSEcCtD
Zuclopenthixol—Vertigo—Methotrexate—urinary bladder cancer	0.000718	0.000751	CcSEcCtD
Zuclopenthixol—Leukopenia—Methotrexate—urinary bladder cancer	0.000716	0.000749	CcSEcCtD
Zuclopenthixol—Arrhythmia—Doxorubicin—urinary bladder cancer	0.00071	0.000743	CcSEcCtD
Zuclopenthixol—Nausea—Cisplatin—urinary bladder cancer	0.000706	0.000739	CcSEcCtD
Zuclopenthixol—Vision blurred—Epirubicin—urinary bladder cancer	0.000705	0.000738	CcSEcCtD
Zuclopenthixol—Mental disorder—Doxorubicin—urinary bladder cancer	0.000697	0.000729	CcSEcCtD
Zuclopenthixol—Ill-defined disorder—Epirubicin—urinary bladder cancer	0.000694	0.000726	CcSEcCtD
Zuclopenthixol—Convulsion—Methotrexate—urinary bladder cancer	0.000693	0.000725	CcSEcCtD
Zuclopenthixol—Vomiting—Etoposide—urinary bladder cancer	0.000693	0.000725	CcSEcCtD
Zuclopenthixol—Malnutrition—Doxorubicin—urinary bladder cancer	0.000692	0.000724	CcSEcCtD
Zuclopenthixol—Erythema—Doxorubicin—urinary bladder cancer	0.000692	0.000724	CcSEcCtD
Zuclopenthixol—Agitation—Epirubicin—urinary bladder cancer	0.000688	0.000719	CcSEcCtD
Zuclopenthixol—Rash—Etoposide—urinary bladder cancer	0.000687	0.000719	CcSEcCtD
Zuclopenthixol—Dermatitis—Etoposide—urinary bladder cancer	0.000686	0.000718	CcSEcCtD
Zuclopenthixol—Headache—Etoposide—urinary bladder cancer	0.000682	0.000714	CcSEcCtD
Zuclopenthixol—Flatulence—Doxorubicin—urinary bladder cancer	0.000682	0.000714	CcSEcCtD
Zuclopenthixol—Myalgia—Methotrexate—urinary bladder cancer	0.000681	0.000712	CcSEcCtD
Zuclopenthixol—Tension—Doxorubicin—urinary bladder cancer	0.000679	0.000711	CcSEcCtD
Zuclopenthixol—Unspecified disorder of skin and subcutaneous tissue—Methotrexate—urinary bladder cancer	0.000676	0.000707	CcSEcCtD
Zuclopenthixol—Malaise—Epirubicin—urinary bladder cancer	0.000675	0.000706	CcSEcCtD
Zuclopenthixol—Discomfort—Methotrexate—urinary bladder cancer	0.000672	0.000703	CcSEcCtD
Zuclopenthixol—Nervousness—Doxorubicin—urinary bladder cancer	0.000672	0.000703	CcSEcCtD
Zuclopenthixol—HRH1—lymph node—urinary bladder cancer	0.000672	0.0152	CbGeAlD
Zuclopenthixol—Vertigo—Epirubicin—urinary bladder cancer	0.000672	0.000703	CcSEcCtD
Zuclopenthixol—Syncope—Epirubicin—urinary bladder cancer	0.000671	0.000702	CcSEcCtD
Zuclopenthixol—Leukopenia—Epirubicin—urinary bladder cancer	0.00067	0.000701	CcSEcCtD
Zuclopenthixol—Palpitations—Epirubicin—urinary bladder cancer	0.000661	0.000692	CcSEcCtD
Zuclopenthixol—ADRA2A—lymph node—urinary bladder cancer	0.00066	0.015	CbGeAlD
Zuclopenthixol—Loss of consciousness—Epirubicin—urinary bladder cancer	0.000658	0.000688	CcSEcCtD
Zuclopenthixol—Anaphylactic shock—Methotrexate—urinary bladder cancer	0.000652	0.000683	CcSEcCtD
Zuclopenthixol—Vision blurred—Doxorubicin—urinary bladder cancer	0.000652	0.000683	CcSEcCtD
Zuclopenthixol—Convulsion—Epirubicin—urinary bladder cancer	0.000648	0.000678	CcSEcCtD
Zuclopenthixol—Nausea—Etoposide—urinary bladder cancer	0.000647	0.000677	CcSEcCtD
Zuclopenthixol—Hypertension—Epirubicin—urinary bladder cancer	0.000646	0.000676	CcSEcCtD
Zuclopenthixol—Ill-defined disorder—Doxorubicin—urinary bladder cancer	0.000642	0.000672	CcSEcCtD
Zuclopenthixol—Nervous system disorder—Methotrexate—urinary bladder cancer	0.00064	0.000669	CcSEcCtD
Zuclopenthixol—Thrombocytopenia—Methotrexate—urinary bladder cancer	0.000639	0.000668	CcSEcCtD
Zuclopenthixol—Myalgia—Epirubicin—urinary bladder cancer	0.000637	0.000666	CcSEcCtD
Zuclopenthixol—Agitation—Doxorubicin—urinary bladder cancer	0.000636	0.000666	CcSEcCtD
Zuclopenthixol—Anxiety—Epirubicin—urinary bladder cancer	0.000635	0.000664	CcSEcCtD
Zuclopenthixol—Skin disorder—Methotrexate—urinary bladder cancer	0.000634	0.000663	CcSEcCtD
Zuclopenthixol—Unspecified disorder of skin and subcutaneous tissue—Epirubicin—urinary bladder cancer	0.000633	0.000662	CcSEcCtD
Zuclopenthixol—Hyperhidrosis—Methotrexate—urinary bladder cancer	0.000631	0.00066	CcSEcCtD
Zuclopenthixol—Discomfort—Epirubicin—urinary bladder cancer	0.000629	0.000658	CcSEcCtD
Zuclopenthixol—Malaise—Doxorubicin—urinary bladder cancer	0.000624	0.000653	CcSEcCtD
Zuclopenthixol—Dry mouth—Epirubicin—urinary bladder cancer	0.000623	0.000652	CcSEcCtD
Zuclopenthixol—Vertigo—Doxorubicin—urinary bladder cancer	0.000622	0.000651	CcSEcCtD
Zuclopenthixol—Anorexia—Methotrexate—urinary bladder cancer	0.000622	0.000651	CcSEcCtD
Zuclopenthixol—Syncope—Doxorubicin—urinary bladder cancer	0.000621	0.000649	CcSEcCtD
Zuclopenthixol—Leukopenia—Doxorubicin—urinary bladder cancer	0.00062	0.000648	CcSEcCtD
Zuclopenthixol—Palpitations—Doxorubicin—urinary bladder cancer	0.000612	0.00064	CcSEcCtD
Zuclopenthixol—Anaphylactic shock—Epirubicin—urinary bladder cancer	0.000611	0.000639	CcSEcCtD
Zuclopenthixol—Hypotension—Methotrexate—urinary bladder cancer	0.00061	0.000638	CcSEcCtD
Zuclopenthixol—Loss of consciousness—Doxorubicin—urinary bladder cancer	0.000608	0.000637	CcSEcCtD
Zuclopenthixol—Shock—Epirubicin—urinary bladder cancer	0.000601	0.000628	CcSEcCtD
Zuclopenthixol—Convulsion—Doxorubicin—urinary bladder cancer	0.0006	0.000627	CcSEcCtD
Zuclopenthixol—Nervous system disorder—Epirubicin—urinary bladder cancer	0.000599	0.000626	CcSEcCtD
Zuclopenthixol—Thrombocytopenia—Epirubicin—urinary bladder cancer	0.000598	0.000625	CcSEcCtD
Zuclopenthixol—Hypertension—Doxorubicin—urinary bladder cancer	0.000598	0.000625	CcSEcCtD
Zuclopenthixol—Tachycardia—Epirubicin—urinary bladder cancer	0.000596	0.000623	CcSEcCtD
Zuclopenthixol—Musculoskeletal discomfort—Methotrexate—urinary bladder cancer	0.000594	0.000622	CcSEcCtD
Zuclopenthixol—Skin disorder—Epirubicin—urinary bladder cancer	0.000593	0.00062	CcSEcCtD
Zuclopenthixol—Hyperhidrosis—Epirubicin—urinary bladder cancer	0.00059	0.000618	CcSEcCtD
Zuclopenthixol—Insomnia—Methotrexate—urinary bladder cancer	0.00059	0.000617	CcSEcCtD
Zuclopenthixol—Myalgia—Doxorubicin—urinary bladder cancer	0.000589	0.000617	CcSEcCtD
Zuclopenthixol—Anxiety—Doxorubicin—urinary bladder cancer	0.000587	0.000614	CcSEcCtD
Zuclopenthixol—Paraesthesia—Methotrexate—urinary bladder cancer	0.000586	0.000613	CcSEcCtD
Zuclopenthixol—Unspecified disorder of skin and subcutaneous tissue—Doxorubicin—urinary bladder cancer	0.000585	0.000612	CcSEcCtD
Zuclopenthixol—Discomfort—Doxorubicin—urinary bladder cancer	0.000582	0.000609	CcSEcCtD
Zuclopenthixol—Anorexia—Epirubicin—urinary bladder cancer	0.000582	0.000609	CcSEcCtD
Zuclopenthixol—Dyspnoea—Methotrexate—urinary bladder cancer	0.000582	0.000609	CcSEcCtD
Zuclopenthixol—Somnolence—Methotrexate—urinary bladder cancer	0.00058	0.000607	CcSEcCtD
Zuclopenthixol—Dry mouth—Doxorubicin—urinary bladder cancer	0.000576	0.000603	CcSEcCtD
Zuclopenthixol—Dyspepsia—Methotrexate—urinary bladder cancer	0.000574	0.000601	CcSEcCtD
Zuclopenthixol—Hypotension—Epirubicin—urinary bladder cancer	0.000571	0.000597	CcSEcCtD
Zuclopenthixol—Decreased appetite—Methotrexate—urinary bladder cancer	0.000567	0.000593	CcSEcCtD
Zuclopenthixol—Anaphylactic shock—Doxorubicin—urinary bladder cancer	0.000565	0.000591	CcSEcCtD
Zuclopenthixol—Gastrointestinal disorder—Methotrexate—urinary bladder cancer	0.000563	0.000589	CcSEcCtD
Zuclopenthixol—Fatigue—Methotrexate—urinary bladder cancer	0.000563	0.000588	CcSEcCtD
Zuclopenthixol—Pain—Methotrexate—urinary bladder cancer	0.000558	0.000584	CcSEcCtD
Zuclopenthixol—Musculoskeletal discomfort—Epirubicin—urinary bladder cancer	0.000556	0.000582	CcSEcCtD
Zuclopenthixol—Shock—Doxorubicin—urinary bladder cancer	0.000556	0.000581	CcSEcCtD
Zuclopenthixol—Nervous system disorder—Doxorubicin—urinary bladder cancer	0.000554	0.00058	CcSEcCtD
Zuclopenthixol—Thrombocytopenia—Doxorubicin—urinary bladder cancer	0.000553	0.000579	CcSEcCtD
Zuclopenthixol—Insomnia—Epirubicin—urinary bladder cancer	0.000552	0.000578	CcSEcCtD
Zuclopenthixol—Tachycardia—Doxorubicin—urinary bladder cancer	0.000551	0.000577	CcSEcCtD
Zuclopenthixol—Skin disorder—Doxorubicin—urinary bladder cancer	0.000549	0.000574	CcSEcCtD
Zuclopenthixol—Paraesthesia—Epirubicin—urinary bladder cancer	0.000548	0.000574	CcSEcCtD
Zuclopenthixol—Hyperhidrosis—Doxorubicin—urinary bladder cancer	0.000546	0.000571	CcSEcCtD
Zuclopenthixol—Dyspnoea—Epirubicin—urinary bladder cancer	0.000544	0.000569	CcSEcCtD
Zuclopenthixol—Somnolence—Epirubicin—urinary bladder cancer	0.000543	0.000568	CcSEcCtD
Zuclopenthixol—Anorexia—Doxorubicin—urinary bladder cancer	0.000539	0.000563	CcSEcCtD
Zuclopenthixol—Feeling abnormal—Methotrexate—urinary bladder cancer	0.000538	0.000562	CcSEcCtD
Zuclopenthixol—Dyspepsia—Epirubicin—urinary bladder cancer	0.000537	0.000562	CcSEcCtD
Zuclopenthixol—Gastrointestinal pain—Methotrexate—urinary bladder cancer	0.000534	0.000558	CcSEcCtD
Zuclopenthixol—Decreased appetite—Epirubicin—urinary bladder cancer	0.000531	0.000555	CcSEcCtD
Zuclopenthixol—Hypotension—Doxorubicin—urinary bladder cancer	0.000528	0.000552	CcSEcCtD
Zuclopenthixol—Gastrointestinal disorder—Epirubicin—urinary bladder cancer	0.000527	0.000551	CcSEcCtD
Zuclopenthixol—Fatigue—Epirubicin—urinary bladder cancer	0.000526	0.000551	CcSEcCtD
Zuclopenthixol—Constipation—Epirubicin—urinary bladder cancer	0.000522	0.000546	CcSEcCtD
Zuclopenthixol—Pain—Epirubicin—urinary bladder cancer	0.000522	0.000546	CcSEcCtD
Zuclopenthixol—Body temperature increased—Methotrexate—urinary bladder cancer	0.000516	0.00054	CcSEcCtD
Zuclopenthixol—Abdominal pain—Methotrexate—urinary bladder cancer	0.000516	0.00054	CcSEcCtD
Zuclopenthixol—Musculoskeletal discomfort—Doxorubicin—urinary bladder cancer	0.000515	0.000538	CcSEcCtD
Zuclopenthixol—Insomnia—Doxorubicin—urinary bladder cancer	0.000511	0.000535	CcSEcCtD
Zuclopenthixol—Paraesthesia—Doxorubicin—urinary bladder cancer	0.000507	0.000531	CcSEcCtD
Zuclopenthixol—Dyspnoea—Doxorubicin—urinary bladder cancer	0.000504	0.000527	CcSEcCtD
Zuclopenthixol—Feeling abnormal—Epirubicin—urinary bladder cancer	0.000503	0.000526	CcSEcCtD
Zuclopenthixol—Somnolence—Doxorubicin—urinary bladder cancer	0.000502	0.000525	CcSEcCtD
Zuclopenthixol—Gastrointestinal pain—Epirubicin—urinary bladder cancer	0.000499	0.000522	CcSEcCtD
Zuclopenthixol—Dyspepsia—Doxorubicin—urinary bladder cancer	0.000497	0.00052	CcSEcCtD
Zuclopenthixol—Decreased appetite—Doxorubicin—urinary bladder cancer	0.000491	0.000514	CcSEcCtD
Zuclopenthixol—Gastrointestinal disorder—Doxorubicin—urinary bladder cancer	0.000488	0.00051	CcSEcCtD
Zuclopenthixol—Fatigue—Doxorubicin—urinary bladder cancer	0.000487	0.00051	CcSEcCtD
Zuclopenthixol—Pain—Doxorubicin—urinary bladder cancer	0.000483	0.000505	CcSEcCtD
Zuclopenthixol—Constipation—Doxorubicin—urinary bladder cancer	0.000483	0.000505	CcSEcCtD
Zuclopenthixol—Abdominal pain—Epirubicin—urinary bladder cancer	0.000483	0.000505	CcSEcCtD
Zuclopenthixol—Body temperature increased—Epirubicin—urinary bladder cancer	0.000483	0.000505	CcSEcCtD
Zuclopenthixol—Hypersensitivity—Methotrexate—urinary bladder cancer	0.000481	0.000503	CcSEcCtD
Zuclopenthixol—Asthenia—Methotrexate—urinary bladder cancer	0.000468	0.00049	CcSEcCtD
Zuclopenthixol—Feeling abnormal—Doxorubicin—urinary bladder cancer	0.000466	0.000487	CcSEcCtD
Zuclopenthixol—Gastrointestinal pain—Doxorubicin—urinary bladder cancer	0.000462	0.000483	CcSEcCtD
Zuclopenthixol—Pruritus—Methotrexate—urinary bladder cancer	0.000462	0.000483	CcSEcCtD
Zuclopenthixol—Hypersensitivity—Epirubicin—urinary bladder cancer	0.00045	0.000471	CcSEcCtD
Zuclopenthixol—Body temperature increased—Doxorubicin—urinary bladder cancer	0.000447	0.000467	CcSEcCtD
Zuclopenthixol—Abdominal pain—Doxorubicin—urinary bladder cancer	0.000447	0.000467	CcSEcCtD
Zuclopenthixol—Diarrhoea—Methotrexate—urinary bladder cancer	0.000446	0.000467	CcSEcCtD
Zuclopenthixol—Asthenia—Epirubicin—urinary bladder cancer	0.000438	0.000458	CcSEcCtD
Zuclopenthixol—Pruritus—Epirubicin—urinary bladder cancer	0.000432	0.000452	CcSEcCtD
Zuclopenthixol—Dizziness—Methotrexate—urinary bladder cancer	0.000431	0.000451	CcSEcCtD
Zuclopenthixol—Diarrhoea—Epirubicin—urinary bladder cancer	0.000418	0.000437	CcSEcCtD
Zuclopenthixol—Hypersensitivity—Doxorubicin—urinary bladder cancer	0.000416	0.000435	CcSEcCtD
Zuclopenthixol—Vomiting—Methotrexate—urinary bladder cancer	0.000415	0.000434	CcSEcCtD
Zuclopenthixol—Rash—Methotrexate—urinary bladder cancer	0.000411	0.00043	CcSEcCtD
Zuclopenthixol—Dermatitis—Methotrexate—urinary bladder cancer	0.000411	0.00043	CcSEcCtD
Zuclopenthixol—Headache—Methotrexate—urinary bladder cancer	0.000409	0.000428	CcSEcCtD
Zuclopenthixol—Asthenia—Doxorubicin—urinary bladder cancer	0.000405	0.000424	CcSEcCtD
Zuclopenthixol—Dizziness—Epirubicin—urinary bladder cancer	0.000404	0.000422	CcSEcCtD
Zuclopenthixol—Pruritus—Doxorubicin—urinary bladder cancer	0.0004	0.000418	CcSEcCtD
Zuclopenthixol—Vomiting—Epirubicin—urinary bladder cancer	0.000388	0.000406	CcSEcCtD
Zuclopenthixol—Nausea—Methotrexate—urinary bladder cancer	0.000388	0.000405	CcSEcCtD
Zuclopenthixol—Diarrhoea—Doxorubicin—urinary bladder cancer	0.000387	0.000404	CcSEcCtD
Zuclopenthixol—Rash—Epirubicin—urinary bladder cancer	0.000385	0.000403	CcSEcCtD
Zuclopenthixol—Dermatitis—Epirubicin—urinary bladder cancer	0.000385	0.000402	CcSEcCtD
Zuclopenthixol—Headache—Epirubicin—urinary bladder cancer	0.000383	0.0004	CcSEcCtD
Zuclopenthixol—Dizziness—Doxorubicin—urinary bladder cancer	0.000374	0.000391	CcSEcCtD
Zuclopenthixol—Nausea—Epirubicin—urinary bladder cancer	0.000363	0.000379	CcSEcCtD
Zuclopenthixol—Vomiting—Doxorubicin—urinary bladder cancer	0.000359	0.000376	CcSEcCtD
Zuclopenthixol—Rash—Doxorubicin—urinary bladder cancer	0.000356	0.000373	CcSEcCtD
Zuclopenthixol—Dermatitis—Doxorubicin—urinary bladder cancer	0.000356	0.000372	CcSEcCtD
Zuclopenthixol—Headache—Doxorubicin—urinary bladder cancer	0.000354	0.00037	CcSEcCtD
Zuclopenthixol—Nausea—Doxorubicin—urinary bladder cancer	0.000336	0.000351	CcSEcCtD
